A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites
Study sponsor: BioVie Inc. · BIVI
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-05-08Actual
Enrollment · participants15Actual
Source updated2024-05-08Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.